Concepedia

Miguel Islas‐Ohlmayer

MI

9

Publications

1.3K

Citations

9

H-Index

2003

Active since

Affiliations

Seagen (United States)(Current)

Texas Oncology

Columbia University Irving Medical Center

Hematology Oncology Associates

The University of Texas Southwestern Medical Center

Miguel Islas‐Ohlmayer is an author at Seagen (United States) specializing in immunomodulation, allergy, and hematology.

Top concepts

Publications per year

2003–2024

9

Publications

9

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

Steven M. Horwitz, Owen A. O’Connor, Barbara Pro et al. · The Lancet · 2018 · 707 citations · Full text

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

Ann S. LaCasce, R. Gregory Bociek, Ahmed Sawas et al. · Blood · 2018 · 246 citations · Full text

Cost and Clinical Analysis of Autologous Hematopoietic Stem Cell Mobilization with G-CSF and Plerixafor Compared to G-CSF and Cyclophosphamide

Paul Shaughnessy, Miguel Islas‐Ohlmayer, Julie A. Murphy et al. · Biology of Blood and Marrow Transplantation · 2010 · 88 citations

Experimental Infection of NOD/SCID Mice Reconstituted with Human CD34 <sup>+</sup> Cells with Epstein-Barr Virus

Miguel Islas‐Ohlmayer, Angela Padgett‐Thomas, Rana Domiati‐Saad et al. · Journal of Virology · 2004 · 69 citations · Full text

Brentuximab Vedotin Plus Bendamustine: A Highly Active Salvage Treatment Regimen for Patients with Relapsed or Refractory Hodgkin Lymphoma

Ann S. LaCasce, Gregory Bociek, Ahmed Sawas et al. · Blood · 2015 · 61 citations

Rows per page

1–5 of 9